CTLA-4 inhibitors expand the diversity of the initial T cell pool and enhance the anti-tumor immune response by targeting the co inhibitory signal at the early T cell activation stage and destroying the competitive inhibition of the CD28 co-stimulatory pathway [54]. Here, CTLA4 is linked to neoplasm.